Board Meeting Details

The Board Meeting was held on Sunday, November 1, 2026, at 12:30 p.m. at the Registered Office of the Company in Hyderabad. The meeting concluded at 2:30 p.m.

Key Decisions and Approvals

The Board considered and approved the following matters:

1. Unaudited Financial Results: Approved the unaudited financial results (Standalone and Consolidated) for the quarter and half year ended September 30, 2026.

2. Limited Review Reports: Approved the Limited Review Reports (Standalone and Consolidated) for the quarter and half year ended September 30, 2026.

3. Acquisition of SP Analytics: Approved the acquisition of the remaining 25% equity shareholding in M/s. SP Analytics Private Limited, a subsidiary in which the company already held 75%, making it a wholly-owned subsidiary.

  • Target Entity: SP Analytics Private Limited
  • Industry: Pharma Sector
  • Transaction Type: Related Party Transaction (RPT) as the entity is a related party
  • Consideration: Cash payment of ₹25,000 for 2,500 equity shares of face value ₹10 each
  • Completion Timeline: On or before December 31, 2026
  • Background: SP Analytics was incorporated on November 16, 2023, with the main object of undertaking testing, analysis and examination of pharmaceuticals, medicines, drugs and related materials. The company reported nil turnover during the last three financial years.

4. Constitution of Management Committee: Approved the constitution of a Management Committee for smooth functioning and administrative convenience of the Company.

  • Committee Members:
  • Anil Kumar Karusala (Managing Director) - Chairman
  • Vijitha Gorrepati (Whole Time Director) - Member
  • Kunal Kakumanu (Executive Director) - Member
  • Arvind Gannimitta (Chief Operating Officer) - Member
  • Ashwani Singh Bisht (Company Secretary & Compliance Officer) - Member

5. Completion of Saicriti Pharma Acquisition: Noted the completion of the acquisition of 60% of the equity share capital of Saicriti Pharma Private Limited, pursuant to the Board approval granted on August 11, 2026. Consequently, Saicriti Pharma Private Limited has become a subsidiary of the Company with effect from the date of completion of the acquisition.

Financial Results Highlights (Consolidated)

For Quarter Ended September 30, 2026:

  • Total Income: ₹389.18 million
  • Total Expenses: ₹188.70 million
  • Profit Before Tax: ₹98.89 million
  • Profit After Tax: ₹79.23 million
  • Basic EPS: ₹2.38

For Half Year Ended September 30, 2026:

  • Total Income: ₹381.05 million
  • Total Expenses: ₹361.37 million
  • Profit Before Tax: ₹196.79 million
  • Profit After Tax: ₹105.10 million
  • Basic EPS: ₹4.17

Financial Results Highlights (Standalone)

For Quarter Ended September 30, 2026:

  • Total Income: ₹565.01 million
  • Total Expenses: ₹478.04 million
  • Profit Before Tax: ₹86.97 million
  • Profit After Tax: ₹64.86 million
  • Basic EPS: ₹1.47

For Half Year Ended September 30, 2026:

  • Total Income: ₹1,126.93 million
  • Total Expenses: ₹921.66 million
  • Profit Before Tax: ₹205.27 million
  • Profit After Tax: ₹153.61 million
  • Basic EPS: ₹3.48

Balance Sheet Position (Consolidated as of September 30, 2026)

  • Total Assets: ₹13,198.08 million
  • Total Equity: ₹5,081.03 million
  • Total Liabilities: ₹8,117.05 million
  • Cash and Cash Equivalents: ₹1,293.30 million

Auditor Review

The unaudited financial results were reviewed by the statutory auditors, R Kabra & Co. LLP, who issued an unmodified conclusion on both standalone and consolidated results. The review was conducted in accordance with Standard on Review Engagements (SRE) 2410 issued by ICAI.